Max Hodak, CEO of Science Corp, plans to unveil a bold thesis at TechCrunch Disrupt 2026: the era of screens is ending. The neurotechnology entrepreneur will present his vision for screen-free interfaces designed to replace the devices that have dominated human-computer interaction for decades.
Science Corp emerged from Hodak's work in brain-computer interfaces and neural engineering. The company focuses on developing direct neural pathways for human cognition and communication, sidestepping traditional input methods like keyboards, mice, and touchscreens. Hodak's earlier venture, Neuralink (where he served as president before departing in 2021), pioneered invasive brain-machine interfaces. Science Corp takes a different approach, exploring non-invasive or minimally invasive neural technologies.
The timing of Hodak's Disrupt appearance reflects growing momentum in the neural interface space. Companies like Neuralink, Synchron, and BrainGate have demonstrated proof-of-concept systems allowing paralyzed patients to control cursors and type with thought alone. These breakthroughs have attracted billions in venture funding and regulatory attention from the FDA. Yet most existing solutions remain tethered to screens for output and feedback.
Hodak's screen-free vision extends beyond convenience. He specifically highlights medical applications, suggesting neural interfaces could offer diagnostic or therapeutic benefits beyond replacing your smartphone. This positions Science Corp at the intersection of healthcare technology and consumer computing. A brain-computer interface that both eliminates screens and delivers medical value addresses two massive markets simultaneously: the multi-trillion-dollar smartphone/computing industry and the healthcare sector.
The announcement comes as the tech industry broadly questions screen dependency. Apple, Meta, and other giants have invested heavily in spatial computing and augmented reality as alternatives. Yet Hodak's approach skips the intermediate step entirely. Rather than replacing a screen with glasses or a headset, he proposes removing the screen altogether through direct neural communication.
Science Corp's funding status remains unclear from available information, but Hodak's track record suggests investor appetite exists. His previous neural technology ventures attracted leading venture firms and strategic capital. The company likely faces intense competition from Neuralink (with its established animal testing protocols and FDA breakthrough designation), Synchron (which has already implanted systems in human patients), and emerging stealth startups backed by Peter Thiel and other neural tech investors.
Hodak's Disrupt presentation will likely emphasize timelines and technical feasibility. The neural interface market remains early, with most commercial systems still in clinical trials. Consumer viability requires solving engineering challenges around biocompatibility, signal processing, and safety. Hodak's assertion that screens are ending is provocative. It suggests he believes these problems are closer to solved than mainstream observers assume.
The TechCrunch Disrupt 2026 speaking slot gives Hodak a platform to articulate this vision to founders, investors, and technology journalists. His appearance signals that screen-free interfaces have graduated from fringe neuroscience to mainstream venture and startup conversation. Whether the screens era actually ends depends on whether companies like Science Corp can deliver on neural interface promises faster than skeptics expect.